As Cardinal Health (CAH) struggles to resolve its role in the U.S. opioid crisis, the distributor is facing fresh criticism for re-appointing a board member who previously served at a time when the company was fined by federal authorities for allowing controlled substances to be diverted.

Last December, the wholesaler named J. Michael Losh as an independent director and chair of its audit committee which, among other things, helps the board monitor compliance with legal and regulatory requirements. However, a skills matrix in the Cardinal proxy statement noted Losh does not have the operations experience to help the board’s understanding of distribution operations (see page 14).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy